Table 1 Studies with negative results based on most recent trial
Medication | Relevant studies |
|---|---|
Amiloride | Positive results from open-label study (pilot study) [328] |
Negative results from phase 2b clinical trial [317] | |
Biotin (MD1003, high dose) | Positive results from three-centers study (pilot study) [321] |
Positive results from phase 2 clinical trial [322] | |
Negative results from phase 3 clinical trial [323] | |
Dronabinol | Negative results from randomized controlled trial [336] |
Fingolimod | Negative results from phase 3 clinical trial [265] |
Fluoxetine | Negative results from single-center study (pilot study with inadequate power) [337] |
Negative results from phase 2b clinical trial [317] | |
Glatiramer acetate | Negative results from randomized controlled trial [338] |
Idebenone | Negative results from phase 1/2 clinical trial [339] |
Lamotrigine | Negative results from phase 2 clinical trial [340] |
Laquinimod | Negative results from phase 2 clinical trial [341] |
Lenercept | Negative results from phase 2 clinical trial [342] |
Lithium | Negative results from open-label pilot study [343] |
MBP8298 (dirucotide) | Positive results in subgroup of participants from phase 2 clinical trial [344] |
Negative results from phase 3 clinical trial [345] | |
MIS416 | Negative results from phase 2 clinical trial from pharmaceutical company report [346] |
Natalizumab | Positive results from phase 2 clinical trial [347] |
Negative results on sustained disability progression (positive results on upper-limb component of disability) from phase 3 clinical trial [348] | |
Opicinumab | Negative results from phase 2 clinical trial [349] |
Development of opicinumab has been halted by the pharmaceutical company (October 2020) [350] | |
Riluzole | Positive results from pilot study [332] |
Negative results from phase 2b clinical trial [317] | |
Rituximab | Negative results from phase 2/3 clinical trial [351] |